A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group Study.
A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group Study.
复制标题
Didemnin B 的 II 期试验（NSC
DOI：
10.1097/00000421-199302000-00012
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Jacobs,AJ
中科院分区：
文献类型：
--
作者：
Malfetano,JH;Blessing,JA;Jacobs,AJ
16例晚期或复发性上皮性卵巢癌患者在联合化疗后进展，每28天静脉注射4.2 mg/m2的Didemnin B（NSC# 325319），直至疾病进展。所有患者既往均接受过含顺铂化疗。没有回应者。7例患者病情稳定（43.7%），9例（53.3%）病情加重。毒性显著，包括7例患者（44%）的恶心和呕吐、1例3级肝毒性和3例4级毒性（1例白细胞减少症、1例GI和1例GU）。当使用此方案时，Didemnin B对既往接受过治疗的上皮性卵巢癌患者无效。
Sixteen evaluable patients with advanced or recurrent epithelial ovarian carcinoma following progression on combination chemotherapy were treated with 4.2 mg/m 2 of Didemnin B (NSC# 325319) intravenously every 28 days until progression of disease. All patients had prior cisplatin-containing chemotherapy. There were no responders. Seven patients had stable disease (43.7%) and nine (53.3%) had increasing disease. The toxicities were significant, consisting of nausea and vomiting in seven patients (44%), one grade 3 hepatic toxicity, and three instances of grade 4 toxicities (1 leukopenia, 1 GI, and 1 GU). When used with this schedule Didemnin B is ineffective in patients with previously treated epithelial ovarian cancer.